The world's first portable electrocardiograph was an 85-pound backpack, and now a 10-gram patch attached to your chest can transmit electrocardiograms uninterrupted for two weeks. The Apple Watch, which is worn by an estimated 100 million people, can send a text message to alert people when their heartbeat is irregular. Wearable sensors on the arms, wrists and fingers can now report arrhythmias, blood sugar levels, blood oxygen and other health indicators. Medical journals have also proposed a more ambitious vision - wearable devices can monitor patients with chronic diseases, eliminating the need for frequent hospital visits. They can spot potential health problems before a stroke or diabetes develops. The forces of health technology and wearables are converging. Tech giants like Apple (AAPL) and Alphabet's (GOOGL) Google are adding health features to their products. Medical technologists like electrocardiogram patch maker iRhythm Technologies or blood sugar monitor makers DexCom (DXCM) and Abbott Laboratories (ABT) are taking their devices beyond the clinic. "In the sensor world, people started on the consumer side and wanted to get into health care," said Kevin Sayer, chief executive of Decon Medical. "In health care, we're trying to be more consumer oriented, and I think all of those things are sort of colliding." Early bets favored the tech giants, with every health-related announcement from Apple, Google or Samsung Electronics hitting medical tech stocks. But changing doctors' practices will also require sustained investment in clinical trials. Big tech companies have cut back on investments in health care. Now it seems that medical technologists will be at the vanguard of the digital health revolution - with smartwatches and smart rings bringing them more customers who need to be diagnosed. Blake Goodner, co-founder of Bridger Management, a hedge fund focused on health care, said: "A group of medtech companies focused on digital health are maturing and reaching a scale where they can not only be profitable but also make investments to compete with larger tech companies." Tech giants aren't getting out of the health business. Apple's smartwatch has an electronic heart rate sensor that generates a single-point electrocardiogram, a wrist temperature sensor, and an accelerometer that can detect violent falls. Hundreds of millions of people are wearing smartwatches with health features from Apple or its rivals Samsung and Garmin.

On Monday, executives from the three major chip giants in the US - Intel, Qualcomm, and Nvidia - met with US officials, including Antony Blinken, to voice their opposition to the Biden administration's plan of imposing further restrictions on chip sales to Chinese companies and investments in China. The Semiconductor Industry Association also released a similar statement, opposing the exclusion of US semiconductor companies from the Chinese market. First of all, we mustn't believe that the appeals of these companies and industry associations will collectively change the determination of US political elites to stifle China's progress. These US elites are very fearful of China's rapid development, and they see "chip chokehold" as a new discovery and a successful tactic formed under US leadership and with the cooperation of allies. Currently, the chip industry is the most complex technology in human history, with only a few companies being at the forefront. They are mainly from the Netherlands, Taiwan island, South Korea, and Japan, most of which are in the Western Pacific. These countries and regions are heavily influenced by the US. Although these companies have their own expertise, they still use some American technologies in their products. Therefore, Washington quickly persuaded them to form an alliance to collectively prevent the Chinese mainland from obtaining chips and manufacturing technology. Washington is proud of this and wants to continuously tighten the noose on China. The New York Times directly titled an article "'An Act of War': Inside America's Silicon Blockade Against China, " in which an American AI expert, Gregory Allen, publicly claimed that this is an act of war against China. He further stated that there are two dates that will echo in history from 2022: The first is February 24, when the Russia-Ukraine conflict broke out, and the second is October 7, when the US imposed a sweeping set of export controls on selling microchips to China. China must abandon its illusions and launch a challenging and effective counterattack. We already have the capability to produce 28nm chips, and we can use "small chip" technology to assemble small semiconductors into a more powerful "brain," exploring 14nm or even 7nm. Additionally, China is the world's largest commercial market for commodity semiconductors. Last year, semiconductor procurement in China amounted to $180 billion, surpassing one-third of the global total. In the past, China had been faced with the choice between independent innovation and external purchases. Due to the high returns from external purchases, it is easy for it to become the overwhelming choice over independent research and development. However, now the US is gradually blocking the option of external purchases, and China has no strategic choice but to independently innovate, which in turn puts tremendous pressure on American companies. Scientists generally expect that, although China may take some detours, such as recently apprehending several company leaders who fraudulently obtained subsidies from national semiconductor policies, China has the ability to gradually overcome the chip difficulties. And we will form our own breakthroughs and industrial chain, which is expected to put quite a lot of pressure on US companies. If domestic firms acquire half of China's $180 billion per year in chip acquisitions, this would provide a significant boost for the industry as a whole and help it advance steadily. The New York Times refers to the battle on chips as a bet by Washington. "If the controls are successful, they could handicap China for a generation; if they fail, they may backfire spectacularly, hastening the very future the United States is trying desperately to avoid," it argued. Whether it is a war or a game, when the future is uncertain, what US companies hope for most of all is that they can sell simplified versions of high-end chips to China, so that the option of external purchases by China continues to exist and remains attractive. This can not only maintain the interests of the US companies, enabling them to obtain sufficient funds to develop more advanced technologies, but also disrupt China's plans for independent innovation. This idea is entirely based on their own commercial interests and also has a certain political and national strategic appeal. Hence, there is no shortage of supporters within the US government. US Secretary of the Treasury Janet Yellen seems to be one of them, as she has repeatedly stated that the US' restrictions on China will not "fundamentally" hurt China, but will only be "narrowly targeted." The US will balance its strict suppression on China from the perspective of maintaining its technological hegemony, while also leaving some room for China, in order to undermine China's determination to counterattack in terms of independent innovation. China needs to use this mentality of the US to its advantage. On the one hand, China should continue to purchase US chips to maintain its economic fundamentals, and on the other hand, it should firmly support the development of domestic semiconductor companies from both financial and market perspectives. If China were to continue relying on exploiting the gaps in US chip policies in the long term, akin to a dependency on opium, it would only serve to weaken China further as it becomes increasingly addicted. China's market is extremely vast, and its innovation capabilities are generally improving and expanding. Although the chip industry is highly advanced, if there is one country that can win this counterattack, it is China. As long as we resolutely continue on the path of independent innovation, this road will definitely become wider. Various breakthroughs and turning points that are unimaginable today may soon occur.

On the afternoon of July 8, local time, the Vietnamese Ministry of Health issued a notice stating that an 18-year-old girl in the country died of diphtheria. The Ministry of Health asked Nghe An Province and Bac Giang Province to take urgent action to control the epidemic. Diphtheria is an acute respiratory infectious disease caused by Corynebacterium diphtheriae, which is mainly transmitted through droplets and can also be indirectly transmitted by contact with objects containing Corynebacterium diphtheriae. Severe cases may show symptoms of poisoning throughout the body, complicated by myocarditis and peripheral nerve paralysis.

A provocative new study reveals the complex effects of the space environment on human health, providing insight into potential damage to blood, cell structure and the immune system. The study focused on SpaceX's Inspiration4 mission, which successfully sent two men and two women into space in 2021 to orbit the Earth for three days and shed some light on the effects of space travel on the human body. The research data, derived directly from the Inspiration4 mission, shows that even a brief trip to space can significantly damage the human immune system, trigger an inflammatory response, and profoundly affect cell structure. In particular, space travel triggered unprecedented changes in cytokines that play a key role in immune response and muscle regulation but are not usually directly associated with inflammation. In particular, the study found a significant increase in muscle factors, which are physiological responses specific to skeletal muscle cells in microgravity, rather than a simple immune response. Although non-muscular tissues did not show changes in proteins associated with inflammation, specific leg muscles such as soleus and tibialis anterior muscles showed significant signs of metabolic activity, especially increased interleukin in the latter, further enhancing the activation of immune cells.

NEW DELHI, July 9 (Reuters) - India's beleaguered Paytm (PAYT.NS), opens new tab has secured approval from a government panel that oversees investments linked to China to invest 500 million rupees ($6 million) in a key subsidiary, three sources with direct knowledge of the matter said. The approval, which still has to be vetted by the finance ministry, will remove the main stumbling block to the unit, Paytm Payment Services, resuming normal business operations. Paytm Payment Services is one of the biggest remaining parts of the fintech firm's business, accounting for a quarter of consolidated revenue in the financial year ended March 2023. A separate unit, Paytm Payments Bank, was wound down this year by order of the central bank due to persistent compliance issues, triggering a meltdown in Paytm's stock. The government panel had earlier held back approval due to concerns about the 9.88% stake in Paytm held by China's Ant Group. India has intensified scrutiny of Chinese businesses since a 2020 border clash between the two countries. All in all, Paytm has been waiting for the nod from the government panel for about two years and without it, it would have had to also wind down its payment services business, which was forbidden from taking on new customers in March 2023. Once the approval has been formalised, it will be able to seek a so-called "payment aggregator" licence from the Reserve Bank of India. The sources, two of whom are government sources, declined to be identified as the decision has not been formally announced. India's foreign, home, finance and industries ministries, whose representatives sit on the panel, did not reply to emails seeking comment. A Paytm spokesperson said the company does not comment on market speculation. "We will continue to make disclosures in compliance with our obligations under the SEBI Regulations, and will inform the exchanges when there is any new material information to share," the spokesperson said.